SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitorsCDK4/6 억제제를 투여받는 유방암 환자의 첫 번째 백신 접종 후 SARS-CoV-2 중화 항체Article Published on 2021-12-012022-09-12 Journal: Breast (Edinburgh, Scotland) [Category] MERS, SARS, 진단, [키워드] Analysis benefit Breast Breast cancer breast cancer patient cancer patient CDK4/6 inhibitors COVID-19 COVID-19 vaccine Critical dose Efficacy and safety first dose first vaccination General population healthy controls immune response inhibitor inhibitors initial neutralizing antibody pandemic post vaccination Protective raised receiving reduce SARS-CoV-2 immunity SARS-CoV-2 neutralizing antibody Treatment vaccination [DOI] 10.1016/j.breast.2021.08.017 PMC 바로가기 [Article Type] Article
COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experienceShort Communication Published on 2021-03-062022-10-28 Journal: The Breast Journal [Category] COVID-19, MERS, [키워드] administration asymptomatic subjects breast cancer patient Cancer cancer centre cancer patient CDK4/6 inhibitors changes in COVID‐19 COVID‐19 Diagnosis disease dose reduction Elective surgery Endocrine Evidence HR positive/HER2 negative metastatic breast cancer increased risk Infection inherent inhibitor institution management neutropenia pandemic positive Radiotherapy receiving receptor recommendation reduction in reflect reported required risk suggested therapy Topic treated Treatment Tumor tumors [DOI] 10.1111/tbj.14204 PMC 바로가기 [Article Type] Short Communication